Astellas Pharma to buy Audentes Therapeutics for USD 2.7 billion
Astellas Pharma offer of $60 per share represents a 110% premium to Audentes closing price on Monday.
New Delhi: Japan’s Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.
Also Read: Astellas Pharma, Seattle Genetics drug shows rapid tumour shrinkage in advanced bladder cancer
Astellas Pharma offer of $60 per share represents a 110% premium to Audentes closing price on Monday.
The deal is expected to close in the first quarter of 2020, the companies said in a statement.
Also Read: Astellas Pharma gets U.S. nod for blood cancer treatment
New Delhi: Japan’s Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.
Also Read: Astellas Pharma, Seattle Genetics drug shows rapid tumour shrinkage in advanced bladder cancer
Astellas Pharma offer of $60 per share represents a 110% premium to Audentes closing price on Monday.
The deal is expected to close in the first quarter of 2020, the companies said in a statement.
Also Read: Astellas Pharma gets U.S. nod for blood cancer treatment
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd